A study from the School of Life Sciences, Tsinghua University, Beijing 100084, China shows that “Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.”
This study was published in the 7 January issue of 2014 Proc Natl Acad Sci U S A (I.F: >10) by Prof Huang L, Wang Z and others from Tsinghua University, Beijing 100084, China.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based therapy for Mammary Cancer: MiRNA-375 suppresses Mammary cancer cell migration and invasion via down regulation of Receptor for hyaluronan-mediated motility (RHAMM)/Hyaluronan-mediated motility receptor (HMMR). This study may suggest that MiRNA-375, by down regulating its target gene, it may inhibit the expression of RHAMM/HMMR. Together, this study suggests that pharmacological formulations encompassing “MiRNA-375 or its activators“ may be used to inhibit cancer metastasis and invasion.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Citation: Boominathan, MiRNA-based therapy for Mammary Cancer: MiRNA-375 suppresses Mammary cancer cell migration and invasion via down regulation of Receptor for hyaluronan-mediated motility (RHAMM)/Hyaluronan-mediated motility receptor (HMMR), 7/October/2014, 15.30, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Significance: This study suggests that miR-375, by decreasing the expression of RHAMM/HMMR, it may (1) inhibit Mammary cancer cell migration and invasion (MCCMI); and (2) serve as an anti-metastatic agent.